Direct and Indirect Proof of SARS-CoV-2 Infections in Indigenous Wiwa Communities in North-Eastern Colombia-A Cross-Sectional Assessment Providing Preliminary Surveillance Data.
COVID-19
Colombia
incidence
indigenous
outbreak
prevalence
surveillance
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
18
08
2021
revised:
27
09
2021
accepted:
28
09
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
To provide initial data on local SARS-CoV-2 epidemiology and spread in indigenous communities in north-eastern Colombia, respiratory swabs and serum samples from volunteers of indigenous communities were examined in March and April 2021. Samples from non-indigenous Colombians from the same villages were included as well. While previous exposure to SARS-CoV-2 was assessed by analysing serum samples for IgG and IgM with a rapid antibody point-of-care-test (POCT), screening for active infections was carried out with an antigen POCT test and real-time PCR from nasal swabs. In 380 indigenous and 72 non-indigenous volunteers, 61 (13.5%) active infections and an additional 113 (25%) previous infections were identified using diagnostic serology and molecular assays. Previous infections were more frequent in non-indigenous volunteers, and relevant associations of clinical features with active or previous SARS-CoV-2 infections were not observed. Symptoms reported were mild to moderate. SARS-CoV-2 was frequent in the assessed Colombian indigenous communities, as 38.5% of the study participants showed signs of exposure to SARS-CoV-2, which confirms the need to include these indigenous communities in screening and vaccination programs.
Identifiants
pubmed: 34696227
pii: vaccines9101120
doi: 10.3390/vaccines9101120
pmc: PMC8539650
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2020 Oct 10;396(10257):1069-1070
pubmed: 33038965
Aust N Z J Public Health. 2020 Aug;44(4):251-252
pubmed: 32583534
J Epidemiol Community Health. 2021 Feb;75(2):207-208
pubmed: 33067253
Am J Trop Med Hyg. 2020 Aug;103(2):609-612
pubmed: 32524964
J Public Health (Oxf). 2021 Jun 7;43(2):e250-e251
pubmed: 33044545
J Clin Med. 2020 May 18;9(5):
pubmed: 32443464
Trop Med Int Health. 2021 Jun;26(6):621-631
pubmed: 33666297
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Microorganisms. 2021 Mar 18;9(3):
pubmed: 33803496
Public Health. 2021 Apr;193:69-75
pubmed: 33743216
CMAJ. 2020 Jul 6;192(27):E787-E788
pubmed: 32631914
Can J Public Health. 2020 Dec;111(6):1000-1001
pubmed: 33170495
Lancet. 2020 Jun 6;395(10239):1753
pubmed: 32505246
Public Health. 2020 Sep;186:127-128
pubmed: 32818726
Psychiatry Res. 2020 Jul;289:113094
pubmed: 32405114
Maturitas. 2020 Jun;136:38-41
pubmed: 32386664
Lancet Glob Health. 2020 Aug;8(8):e1018-e1026
pubmed: 32622400
J Clin Nurs. 2020 Aug;29(15-16):2737-2741
pubmed: 32412150
Nature. 2020 Apr;580(7802):185
pubmed: 32265568
J Clin Med. 2020 Aug 28;9(9):
pubmed: 32872252
BMJ Glob Health. 2021 Jan;6(1):
pubmed: 33414155
BMJ Open. 2020 Dec 29;10(12):e044197
pubmed: 33376182
Science. 2020 Apr 17;368(6488):251
pubmed: 32299940
CMAJ. 2020 Aug 24;192(34):E993-E994
pubmed: 32839171
Int J Infect Dis. 2020 Oct;99:522-529
pubmed: 32791206
PLoS Negl Trop Dis. 2021 Apr 15;15(4):e0009327
pubmed: 33857136
Lancet. 2020 May 30;395(10238):1727-1734
pubmed: 32422124
Science. 2020 Apr 24;368(6489):352
pubmed: 32327576
J Epidemiol Community Health. 2021 Mar 4;:
pubmed: 33674459
Front Med (Lausanne). 2020 Aug 13;7:521
pubmed: 32903503
J Korean Med Sci. 2021 Apr 12;36(14):e101
pubmed: 33847084